Edition:
United Kingdom

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
39,285
52-wk High
$35.70
52-wk Low
$1.35

Latest Key Developments (Source: Significant Developments)

Dare Bioscience Says Entered Into Common Stock Sales Agreement
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Dare Bioscience Inc ::DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING.DARE BIOSCIENCE - UNDER AGREEMENT, CO MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $10 MILLION.  Full Article

Cerulean Pharma says reducing workforce by about 48 pct
Thursday, 18 Aug 2016 

Cerulean Pharma Inc : Cerulean announces reduction in force . Says reducing its workforce by about 48 pct, to a total of 23 full-time equivalent employees . Says expects reduction plan to be substantially completed by end of 2016 . Says workforce reduction is designed to reduce operating expenses while co refocuses its clinical strategy for CRLX101 .Expects reduction in force to result in about $5 million in reduced annualized operating expenses.  Full Article

Cerulean says has enough cash to fund planned ops into Q2 2017
Thursday, 4 Aug 2016 

Cerulean Pharma Inc : Cerulean reports second quarter 2016 corporate highlights and financial results . Believes its cash and cash equivalents are sufficient to fund its planned operations into q2 of 2017 .Qtrly net loss attributable to stockholders for q2 was $10.9 million, compared to net loss attributable to common stockholders of $9.9 million.  Full Article

Cerulean Pharma receives FDA fast track designation for ovarian cancer treatment
Tuesday, 19 Jul 2016 

Cerulean Pharma Inc : Receives FDA fast track designation for CRLX101 for the treatment of platinum-resistant ovarian cancer .Expects to provide an update on CRX101 at European Society For Medical Oncology 2016 Congress.  Full Article

BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil

* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER